TLR signaling modulates side effects of anticancer therapy in the small intestine

Area of Science:

• Innate immunity and inflammation
• Gastrointestinal oncology
• Pharmacology and drug metabolism

Background:

• Intestinal mucositis is a severe complication of chemotherapy, significantly impacting cancer patients' quality of life.
• The exact pathophysiology of chemotherapy-induced intestinal injury is not fully understood, and effective treatments are lacking.
• Innate immunity, particularly Toll-like receptor (TLR) signaling, may play a role in modulating chemotherapy-induced damage.

Purpose of the Study:

• To investigate the role of TLR signaling, specifically TLR2, in chemotherapy-induced small intestinal injury.
• To elucidate the mechanisms by which TLR2 influences xenobiotic metabolism and drug transporter expression.
• To evaluate TLR2 activation as a potential therapeutic strategy for intestinal mucositis.

Main Methods:

• Utilized genetically modified mice (TLR2 knockout) and in vitro cell cultures.
• Administered genotoxic chemotherapy agents and assessed intestinal injury markers (histology, DNA damage, cell infiltration).
• Analyzed gene expression related to xenobiotic metabolism and drug transporters (ABCB1/MDR1 p-gp).
• Investigated the effects of TLR2 stimulation and ligand administration in wild-type and knockout models.
• Confirmed findings in a preclinical model using human duodenal biopsies.

Main Results:

• Genetic deletion of TLR2 exacerbated chemotherapy-induced intestinal mucositis, characterized by villous atrophy and increased DNA damage.
• TLR2 deficiency led to decreased expression of ABCB1/multidrug resistance (MDR)1 p-glycoprotein (p-gp), a key drug efflux transporter.
• TLR2 stimulation enhanced ABCB1/MDR1 p-gp synthesis and activity in myeloid cells, reducing chemotherapy cytotoxicity.
• TLR2 activation protected against injury in wild-type mice but not in MDR1A-deficient mice, highlighting the role of p-gp.
• Antibiotic-induced gut microbiota depletion increased susceptibility to injury, which was ameliorated by TLR2 ligand administration.
• Human duodenal biopsies confirmed that TLR2 activation reduced toxic-inflammatory reactions and maintained p-gp expression.

Conclusions:

• This study identifies a novel link between innate immunity (TLR2) and xenobiotic metabolism in the context of intestinal mucositis.
• TLR2 functions as a critical regulator of the xenobiotic defense system through its modulation of the ABCB1/MDR1 p-gp transporter.
• Targeting TLR2 presents a promising therapeutic avenue for preventing and treating chemotherapy-induced intestinal mucositis.